JP2016214107A - Production method of powder composition containing dead cell of lactic acid bacterium and/or bifidobacterium - Google Patents
Production method of powder composition containing dead cell of lactic acid bacterium and/or bifidobacterium Download PDFInfo
- Publication number
- JP2016214107A JP2016214107A JP2015100273A JP2015100273A JP2016214107A JP 2016214107 A JP2016214107 A JP 2016214107A JP 2015100273 A JP2015100273 A JP 2015100273A JP 2015100273 A JP2015100273 A JP 2015100273A JP 2016214107 A JP2016214107 A JP 2016214107A
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- acid bacteria
- bifidobacteria
- composition containing
- powder composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
本発明は、水性媒体への分散性に優れ、飲料等の風味を変化させない乳酸菌及び／又はビフィズス菌を含有する組成物の製造方法に関する。 The present invention relates to a method for producing a composition containing lactic acid bacteria and / or bifidobacteria that is excellent in dispersibility in an aqueous medium and does not change the flavor of a beverage or the like.
乳酸菌及び／又はビフィズス菌を含有する組成物は、医薬品や食品分野で用いられている。 Compositions containing lactic acid bacteria and / or bifidobacteria are used in the pharmaceutical and food fields.
前記乳酸菌及び／又はビフィズス菌を含有する組成物の製造方法としては、様々な方法が提案されている。
例えば、流動層乾燥機を使用し、流動層中で分散している脱脂粉乳、米粉、もしくは小麦粉に、１０から２０％（最終濃度）のシュークロース水溶液に懸濁した乳酸菌を噴霧し、乳酸菌を生きたまま乾燥させる方法（例えば、特許文献１参照）、粒状物としての賦形剤に結合剤を吹き付け、造粒を行い、造粒物を得る工程と、乳酸菌懸濁液を噴霧乾燥すると同時に前記造粒物と混合する工程とを含む方法（例えば、特許文献２参照）などが提案されている。
また、前記乳酸菌及び／又はビフィズス菌を含有する組成物としては、ミネラル成分を高濃度で含む乳酸菌を含んでなる、水性媒体に分散・溶解して用いる組成物も提案されている（例えば、特許文献３参照）。前記提案では、乳酸菌とその他の配合成分とを混合し、前記混合物に対し水をバインダーとして、流動層造粒装置を用いて造粒し、組成物を製造している。
Various methods have been proposed for producing a composition containing the lactic acid bacteria and / or bifidobacteria.
For example, using a fluidized bed dryer, spray lactic acid bacteria suspended in 10-20% (final concentration) sucrose aqueous solution onto skim milk powder, rice flour, or wheat flour dispersed in the fluidized bed. A method of drying alive (see, for example, Patent Document 1), a step of spraying a binder on an excipient as a granule, granulating and obtaining a granulated product, and simultaneously spray-drying a lactic acid bacteria suspension A method including a step of mixing with the granulated product (for example, see Patent Document 2) has been proposed.
In addition, as a composition containing the lactic acid bacterium and / or bifidobacteria, a composition that contains a lactic acid bacterium containing a mineral component at a high concentration and is used by being dispersed and dissolved in an aqueous medium has been proposed (for example, patents). Reference 3). In the above proposal, a lactic acid bacterium and other blending components are mixed, and the mixture is granulated using a fluidized bed granulator using water as a binder to produce a composition.
しかしながら、特許文献１〜２では生菌を使用している。生菌粉末製剤では水分の影響などにより発酵が進行することがあり、不快な臭いの発生など商品価値を減ずることがある。また、生菌処理物を飲料などに分散させた場合、造粒した生菌を液に入れると増殖を始めるので飲料の味や香り等が変化する恐れがある、生産工程では生菌を扱う以上ライン汚染の可能性が消えない、一定の生菌数を確保することが困難なため品質にバラつきが生じやすい、品質を一定に保つためには様々な添加剤を加えたり、加工工程を増やしたりする必要がある、処理物の生菌数はどうしても少なくなるため、生菌の摂取量を増やすには多量に摂取する必要がある、加熱が出来なかったり冷蔵保存する必要がある等、生菌を扱うには様々な問題がある。そのうえ、特別なコーティング等を施していない生菌を摂取しても胃酸により死滅することから、その生菌を摂取する効力はかなり限定的であり、摂取しても生菌数を維持させるには腸溶性のコーティングを施すなど、製造工程を増やす必要がある。
特許文献３は生菌か死菌かは不明だが、水性媒体への分散性は、十分とは言えないという問題がある。例えば、介護補助食品等では患者が飲食する直前に乳酸菌及び／又はビフィズス菌含有粉末組成物を水性媒体に分散させるものがあり、これが手でも素早く出来ないと介護者の負担が増大してしまう。
However, Patent Literatures 1 and 2 use viable bacteria. In the case of live powder preparations, fermentation may proceed due to the influence of moisture, etc., and the commercial value such as generation of unpleasant odor may be reduced. In addition, when the live bacteria-treated product is dispersed in beverages, etc., if the granulated live bacteria are put into the liquid, they will start to grow, so the taste and aroma of the beverage may change. The possibility of line contamination does not disappear, and it is difficult to ensure a certain number of viable bacteria, so the quality tends to vary. To keep the quality constant, various additives are added and the number of processing steps is increased. Since the number of viable bacteria in the processed product is inevitably reduced, it is necessary to ingest a large amount in order to increase the intake of viable bacteria. There are various problems to deal with. In addition, even if you ingest live bacteria that do not have a special coating, etc., they are killed by gastric acid, so the effect of ingesting the live bacteria is quite limited. It is necessary to increase the number of manufacturing processes, such as applying an enteric coating.
Although Patent Document 3 is unclear whether it is live or dead, there is a problem that dispersibility in an aqueous medium is not sufficient. For example, some care supplements or the like disperse a powder composition containing lactic acid bacteria and / or bifidobacteria in an aqueous medium immediately before eating and drinking by the patient. If this cannot be done quickly by hand, the burden on the caregiver will increase.
したがって、水性媒体への分散性に優れ、飲料等の風味を変化させない乳酸菌及び／又はビフィズス菌を含有する組成物の製造方法の速やかな提供が強く求められている。 Therefore, there is a strong demand for prompt provision of a method for producing a composition containing lactic acid bacteria and / or bifidobacteria that is excellent in dispersibility in an aqueous medium and does not change the flavor of beverages and the like.
本発明は、従来における前記諸問題を解決し、以下の目的を達成することを課題とする。即ち、本発明は、水性媒体への分散性に優れ、飲料等の風味を変化させない乳酸菌及び／又はビフィズス菌を含有する組成物を簡易に、短時間で製造できる方法を提供することを目的とする。 An object of the present invention is to solve the above-described problems and achieve the following objects. That is, an object of the present invention is to provide a method capable of easily and easily producing a composition containing lactic acid bacteria and / or bifidobacteria that is excellent in dispersibility in an aqueous medium and does not change the flavor of beverages and the like. To do.
前記課題を解決するための手段としては、以下の通りである。即ち、
＜１＞ 水溶性高分子物質を含む噴霧液に乳酸菌及び／又はビフィズス菌の死菌体を微細に分散させる工程と、
粉剤を仕込んだ流動層造粒装置内で前記噴霧液を噴霧する工程とを含むことを特徴とする乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物の製造方法である。
＜２＞ 水溶性高分子物質がデキストリンを含む前記＜１＞に記載の乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物の製造方法である。
＜３＞ 粉剤がプレバイオティクスを含む前記＜１＞から＜２＞のいずれかに記載の乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物の製造方法である。
Means for solving the problems are as follows. That is,
<1> a step of finely dispersing dead cells of lactic acid bacteria and / or bifidobacteria in a spray solution containing a water-soluble polymer substance;
And spraying the spray liquid in a fluidized bed granulator charged with a powder. A method for producing a microbial and / or bifidobacteria-containing powder composition containing lactic acid bacteria and / or bifidobacteria.
<2> The method for producing a powder composition containing dead cells of lactic acid bacteria and / or bifidobacteria according to <1>, wherein the water-soluble polymer substance contains dextrin.
<3> The method for producing a powder composition containing dead cells of lactic acid bacteria and / or bifidobacteria according to any one of <1> to <2>, wherein the powder contains prebiotics.
本発明によれば、水性媒体への分散性に優れ、飲料等の風味を変化させない乳酸菌及び／又はビフィズス菌を含有する組成物を簡易に、短時間で製造できる方法を提供することができる。そして、前記組成物は菌体含量を多く出来るので少量でも効果があり、加熱も可能で冷蔵保存する必要もなく、味や風味の加工も容易で設計の自由度が高い。また水性媒体への分散性が非常に高いので、飲料への添加が容易であることはもちろん、介護補助食品等でも手早く分散させて使うことが出来る。 ADVANTAGE OF THE INVENTION According to this invention, the method which is excellent in the dispersibility to an aqueous medium and can manufacture the composition containing the lactic acid bacteria and / or bifidobacteria which do not change the flavors of drinks etc. easily can be provided. And since the said composition can make a microbial cell content large, it is effective even if it is small quantity, heating is also possible, it is not necessary to preserve | save refrigerated, processing of a taste and flavor is easy, and the freedom degree of design is high. Moreover, since the dispersibility to an aqueous medium is very high, it is easy to add to beverages, and it can also be quickly dispersed and used in nursing supplements and the like.
（乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物の製造方法）
本発明の乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物の製造方法は、分散工程と、流動層造粒工程とを少なくとも含み、必要に応じて更にその他の工程を含む。
(Method for producing powder composition containing dead cells of lactic acid bacteria and / or bifidobacteria)
The method for producing a dead cell-containing powder composition of lactic acid bacteria and / or bifidobacteria of the present invention includes at least a dispersion step and a fluidized bed granulation step, and further includes other steps as necessary.
＜分散工程＞
前記分散工程は、水溶性高分子物質を含む噴霧液に乳酸菌及び／又はビフィズス菌の死菌体を微細に分散させる工程である。
<Dispersing process>
The dispersion step is a step of finely dispersing lactic acid bacteria and / or bifidobacteria dead cells in a spray solution containing a water-soluble polymer substance.
−噴霧液−
前記噴霧液は、乳酸菌及び／又はビフィズス菌の死菌体と、水溶性高分子物質とを少なくとも含み、必要に応じて更にその他の成分を含む。
-Spray solution-
The spray solution contains at least a dead cell of lactic acid bacteria and / or bifidobacteria and a water-soluble polymer substance, and further contains other components as necessary.
−−乳酸菌及び／又はビフィズス菌の死菌体−−
前記乳酸菌及び／又はビフィズス菌の死菌体は、市販品を使用してもよいし、培養した乳酸菌及び／又はビフィズス菌を死菌化処理したものを使用してもよい。
--Dead cells of lactic acid bacteria and / or bifidobacteria--
As the dead cells of the lactic acid bacteria and / or bifidobacteria, commercially available products may be used, or those obtained by killing the cultured lactic acid bacteria and / or bifidobacteria may be used.
前記乳酸菌及び／又はビフィズス菌を死菌化処理する方法としては、特に制限はなく、公知の方法を適宜選択することができ、例えば、加熱処理などが挙げられる。 There is no restriction | limiting in particular as a method of killing the said lactic acid bacteria and / or bifidobacteria, A well-known method can be selected suitably, For example, heat processing etc. are mentioned.
前記乳酸菌及び／又はビフィズス菌としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、エンテロコッカス属細菌、ラクトバチルス属細菌、ストレプトコッカス属細菌、ラクトコッカス属細菌、ビフィドバクテリウム属細菌、バチルス属細菌、クロストリジウム属細菌などが挙げられる。これらは、１種単独で使用してもよいし、２種以上を併用してもよい。 The lactic acid bacteria and / or bifidobacteria are not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include Enterococcus bacteria, Lactobacillus bacteria, Streptococcus bacteria, Lactococcus bacteria, Bifidobacterium Genus bacteria, Bacillus bacteria, Clostridium bacteria, and the like. These may be used individually by 1 type and may use 2 or more types together.
前記エンテロコッカス属細菌の具体例としては、エンテロコッカス・フェカリス（Ｅｎｔｅｒｏｃｏｃｃｕｓ ｆａｅｃａｌｉｓ）、エンテロコッカス・フェシウム（Ｅ．ｆａｅｃｉｕｍ）などが挙げられる。 Specific examples of the above Enterococcus bacteria is Enterococcus faecalis (Enterococcus faecalis), and the like Enterococcus faecium (E.faecium).
前記ラクトバチルス属細菌の具体例としては、ラクトバチルス・アシドフィルス（Ｌａｃｔｏｂａｃｉｌｌｕｓ ａｃｉｄｐｈｉｌｕｓ）、ラクトバチルス・ガセリ（Ｌ．ｇａｓｓｅｒｉ）、ラクトバチルス・マリ（Ｌ．ｍａｌｉ）、ラクトバチルス・プランタラム（Ｌ．ｐｌａｎｔａｒｕｍ）、ラクトバチルス・ブヒネリ（Ｌ．ｂｕｃｈｎｅｒｉ）、ラクトバチルス・カゼイ（Ｌ．ｃａｓｅｉ）、ラクトバチルス・ジョンソニー（Ｌ．ｊｏｈｎｓｏｎｉｉ）、ラクトバチルス・ガリナラム（Ｌ．ｇａｌｌｉｎａｒｕｍ）、ラクトバチルス・アミロボラス（Ｌ．ａｍｙｌｏｖｏｒｕｓ）、ラクトバチルス・ブレビス（Ｌ．ｂｒｅｖｉｓ）、ラクトバチルス・ラムノーザス（Ｌ．ｒｈａｍｎｏｓｕｓ）、ラクトバチルス・ケフィア（Ｌ．ｋｅｆｉｒ）、ラクトバチルス・パラカゼイ（Ｌ．ｐａｒａｃａｓｅｉ）、ラクトバチルス・クリスパタス（Ｌ．ｃｒｉｓｐａｔｕｓ）などが挙げられる。 Specific examples of the bacterium belonging to the genus Lactobacillus include Lactobacillus acidophilus, Lactobacillus gasseri ( L. gasseri), Lactobacillus mari ( L. mali ), Lactobacillus plantarum ( L. plantarum). , Lactobacillus Buhineri (L.buchneri), Lactobacillus casei (L.casei), Lactobacillus John Sony (L.johnsonii), Lactobacillus Garinaramu (L.gallinarum), Lactobacillus amylovorus (L.amylovorus ), Lactobacillus brevis (L.brevis), Lactobacillus Ramunozasu (L.rhamnosus), Lactobacillus Kefi (L.kefir), Lactobacillus paracasei (L.paracasei), and the like Lactobacillus crispatus (L.crispatus).
前記ストレプトコッカス属細菌の具体例としては、ストレプトコッカス・サーモフィルス（Ｓｔｒｅｐｔｃｏｃｃｕｓ ｔｈｅｒｍｏｐｈｉｌｕｓ）などが挙げられる。 Specific examples of the Streptococcus bacterium, Streptococcus thermophilus (Streptococcus thermophilus), and the like.
前記ラクトコッカス属細菌の具体例としては、ラクトコッカス・ラクチス（Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ）などが挙げられる。 Specific examples of the Lactococcus bacteria include Lactococcus lactis and the like.
前記ビフィドバクテリウム属細菌の具体例としては、ビフィドバクテリウム・ビフィダム（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ｂｉｆｉｄｕｍ）、ビフィドバクテリウム・ロンガム（Ｂ．ｌｏｎｇｕｍ）、ビフィドバクテリウム・アドレスセンティス（Ｂ．ａｄｏｌｅｓｃｅｎｔｉｓ）、ビフィドバクテリウム・インファンティス（Ｂ．ｉｎｆａｎｔｉｓ）、ビフィドバクテリウム・ブレーベ（Ｂ．ｂｒｅｖｅ）、ビフィドバクテリウム・カテヌラータム（Ｂ．ｃａｔｅｎｕｌａｔｕｍ）などが挙げられる。 Specific examples of the Bifidobacterium bacteria, Bifidobacterium bifidum (Bifidobacterium bifidum), Bifidobacterium longum (B. longum), Bifidobacterium address Sen infantis (B.adolescentis), bi Examples thereof include B. infantis ( B. infantis ), Bifidobacterium breve ( B. breve ), Bifidobacterium catenulatum ( B. catenatum ) and the like.
前記バチルス属細菌の具体例としては、バチルス・ズブチリス（Ｂａｃｉｌｌｕｓ ｓｕｂｔｉｌｉｓ）、バチルス・コアグランス（Ｂ．ｃｏａｇｕｌａｎｓ）などが挙げられる。 Specific examples of the Bacillus bacterium, Bacillus subtilis (Bacillus subtilis), and the like Bacillus coagulans (B. coagulans).
前記クロストリジウム属細菌の具体例としては、クロストリジウム・ブチリカム（Ｃｌｏｓｔｏｒｉｄｉｕｍ ｂｕｔｉｌｉｃｕｍ）などが挙げられる。 Specific examples of the Clostridium bacterium, Clostridium butyricum (Clostoridium butilicum) and the like.
前記噴霧液における乳酸菌及び／又はビフィズス菌の死菌体の含有量としては、特に制限はなく、目的に応じて適宜選択することができる。 There is no restriction | limiting in particular as content of the lactic acid bacteria in the said spray liquid, and / or the dead cell body of Bifidobacterium, It can select suitably according to the objective.
−−水溶性高分子物質−−
前記水溶性高分子物質としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、デキストリン、プルラン、水溶性セルロース誘導体、ポリビニルアルコール、ポリビニルピロリドンなどが挙げられる。これらは、１種単独で使用してもよいし、２種以上を併用してもよい。
これらの中でも、コストや作業性の点で、デキストリンを含むことが好ましい。
前記水溶性セルロース誘導体の具体例としては、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシメチルセルロースなどが挙げられる。
--- Water-soluble polymer substance-
There is no restriction | limiting in particular as said water-soluble high molecular substance, According to the objective, it can select suitably, For example, dextrin, a pullulan, a water-soluble cellulose derivative, polyvinyl alcohol, polyvinylpyrrolidone etc. are mentioned. These may be used individually by 1 type and may use 2 or more types together.
Among these, it is preferable to contain dextrin from the viewpoint of cost and workability.
Specific examples of the water-soluble cellulose derivative include hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose and the like.
前記噴霧液における水溶性高分子物質の含有量としては、特に制限はなく、目的に応じて適宜選択することができる。 There is no restriction | limiting in particular as content of the water-soluble polymer substance in the said spray liquid, According to the objective, it can select suitably.
−−その他の成分−−
前記その他の成分としては、本発明の効果を損なわない限り、特に制限はなく、目的に応じて適宜選択することができ、例えば、前記乳酸菌及び／又はビフィズス菌の培養液に含まれる成分などが挙げられる。
-Other ingredients-
The other components are not particularly limited as long as the effects of the present invention are not impaired, and can be appropriately selected according to the purpose. Examples thereof include components contained in the culture solution of the lactic acid bacteria and / or bifidobacteria. Can be mentioned.
−−態様−−
前記噴霧液は、前記水溶性高分子物質を含む水性媒体に前記乳酸菌及び／又はビフィズス菌の死菌体を加えたものであってもよいし、前記乳酸菌及び／又はビフィズス菌の培養液を死菌化処理したものに前記水溶性高分子物質を加えたものであってもよい。
--Aspect--
The spray solution may be obtained by adding the lactic acid bacteria and / or bifidobacteria cells to an aqueous medium containing the water-soluble polymer substance, or dying the lactic acid bacteria and / or bifidobacteria culture solution. What added the said water-soluble polymer substance to what was bactericidal-ized may be used.
前記水性媒体としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、水、アルコール水溶液などが挙げられる。 There is no restriction | limiting in particular as said aqueous medium, According to the objective, it can select suitably, For example, water, alcohol aqueous solution, etc. are mentioned.
−分散−
前記分散工程では、噴霧液中における乳酸菌及び／又はビフィズス菌を菌体一次粒子にまで微粒子化することが好ましい。
前記分散の方法としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、ホモジナイザー、ミキサー、ボールミル、ビーズミル、高圧ホモジナイザーなどを用いる方法が挙げられる。
-Dispersion-
In the dispersion step, it is preferable that the lactic acid bacteria and / or bifidobacteria in the spray liquid are finely divided into primary bacterial particles.
The dispersion method is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a method using a homogenizer, a mixer, a ball mill, a bead mill, a high-pressure homogenizer, and the like.
前記分散の条件としては、特に制限はなく、目的に応じて適宜選択することができる。 There is no restriction | limiting in particular as conditions for the said dispersion | distribution, According to the objective, it can select suitably.
＜流動層造粒工程＞
前記流動層造粒工程は、粉剤を仕込んだ流動層造粒装置内で前記噴霧液を噴霧する工程である。
前記流動層造粒工程により、前記乳酸菌及び／又はビフィズス菌の死菌体が、前記粉剤に固定化される。
<Fluidized bed granulation process>
The fluidized bed granulating step is a step of spraying the spray liquid in a fluidized bed granulating apparatus charged with a powder.
Through the fluidized bed granulation step, dead cells of the lactic acid bacteria and / or bifidobacteria are immobilized on the powder.
−流動層造粒−
前記流動層造粒に用いる装置としては、特に制限はなく、公知の流動層造粒装置を目的に応じて適宜選択することができ、例えば、フローコーター、スパイラフロー、グラニュレックス（いずれもフロイント産業株式会社製）などが挙げられる。
-Fluidized bed granulation-
There is no restriction | limiting in particular as an apparatus used for the said fluidized-bed granulation, A well-known fluidized-bed granulating apparatus can be suitably selected according to the objective, For example, a flow coater, Spiraflow, Granurex (all are Freund industry. Etc.).
−−粉剤−−
前記粉剤としては、特に制限はなく、公知の粉剤を最終製品の目的に応じて適宜選択することができ、例えば、プレバイオティクス、糖類、澱粉又はその分解物、セルロース、ミネラル類、ビタミン類などが挙げられる。これらは、１種単独で使用してもよいし、２種以上を併用してもよい。
これらの中でも、ヒトの健康に有益な効果が得られる点で、プレバイオティクスを含むことがより好ましい。
--- Powder-
The powder is not particularly limited, and a known powder can be appropriately selected according to the purpose of the final product. For example, prebiotics, saccharides, starch or a decomposition product thereof, cellulose, minerals, vitamins, etc. Is mentioned. These may be used individually by 1 type and may use 2 or more types together.
Among these, it is more preferable to include prebiotics in that a beneficial effect on human health can be obtained.
前記プレバイオティクスとしては、特に制限はなく、目的に応じて適宜選択することができ、オリゴ糖、食物繊維などが挙げられる。
前記オリゴ糖の具体例としては、ガラクトオリゴ糖、フラクトオリゴ糖、大豆オリゴ糖、乳果オリゴ糖、キシロオリゴ糖、イソマルオリゴ糖、ラフィノース、ラクチュロース、コーヒー豆マンノオリゴ糖、グルコン酸などが挙げられる。
前記食物繊維の具体例としては、ポリデキストロース、イヌリンなどが挙げられる。
There is no restriction | limiting in particular as said prebiotic, According to the objective, it can select suitably, An oligosaccharide, a dietary fiber, etc. are mentioned.
Specific examples of the oligosaccharide include galactooligosaccharide, fructooligosaccharide, soybean oligosaccharide, dairy oligosaccharide, xylo-oligosaccharide, isomaly-oligosaccharide, raffinose, lactulose, coffee bean manno-oligosaccharide, and gluconic acid.
Specific examples of the dietary fiber include polydextrose and inulin.
前記粉剤の仕込み量としては、特に制限はなく、目的に応じて適宜選択することができる。 There is no restriction | limiting in particular as the preparation amount of the said powder agent, According to the objective, it can select suitably.
−−噴霧−−
前記噴霧液を噴霧する条件としては、特に制限はなく、目的に応じて適宜選択することができる。
--- Spray--
There is no restriction | limiting in particular as conditions for spraying the said spraying liquid, According to the objective, it can select suitably.
前記流動層造粒により、流動性や圧縮成形性などの粉体加工特性を前記乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物に付与することができる。 By the fluidized bed granulation, powder processing characteristics such as fluidity and compression moldability can be imparted to the dead bacterial cell-containing powder composition of the lactic acid bacteria and / or bifidobacteria.
＜その他の工程＞
前記その他の工程としては、本発明の効果を損なわない限り、特に制限はなく、目的に応じて適宜選択することができる。
<Other processes>
The other steps are not particularly limited as long as the effects of the present invention are not impaired, and can be appropriately selected according to the purpose.
本発明の製造方法によれば、水性媒体への分散性に優れ、飲料等の風味を変化させない乳酸菌及び／又はビフィズス菌を含有する組成物を簡易に、短時間で製造することができる。また、凍結乾燥をしたものと異なり、前記乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物は、塊とはなっていないため、使用時に粉砕処理を行わなくてもよい。 According to the production method of the present invention, a composition containing lactic acid bacteria and / or bifidobacteria that is excellent in dispersibility in an aqueous medium and does not change the flavor of a beverage or the like can be produced easily and in a short time. Further, unlike the freeze-dried product, the lactic acid bacteria and / or bifidobacteria-containing dead cell-containing powder composition does not form a lump, and thus does not need to be pulverized during use.
前記乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物は、そのまま、或いは溶液状、懸濁液状などの形状として、若しくは錠剤の有効成分などとして医薬品又は飲食品に好適に用いることができる。中でも、飲料に好適に用いることができる。
前記医薬品又は飲食品の製造方法としては、特に制限はなく、公知の方法を適宜選択することができる。
The dead bacterial cell-containing powder composition of the lactic acid bacteria and / or bifidobacteria can be suitably used as it is, in the form of a solution, a suspension, or the like, or as an active ingredient of a tablet, for a pharmaceutical or a food or drink. Especially, it can use suitably for a drink.
There is no restriction | limiting in particular as a manufacturing method of the said pharmaceutical or food-drinks, A well-known method can be selected suitably.
以下、本発明の実施例を説明するが、本発明は、これらの実施例に何ら限定されるものではない。 Examples of the present invention will be described below, but the present invention is not limited to these examples.
（実施例１：乳酸菌の死菌体含有粉末組成物の製造）
＜分散工程＞
乳酸菌（エンテロコッカス・フェカリス（Ｅｎｔｅｒｏｃｏｃｃｕｓ ｆａｅｃａｌｉｓ））の死菌粉末（ＥＣ−１２、コンビ株式会社製；菌数 ５兆個／ｇ） １．０ｇを、デキストリン（パインデックス＃２、松谷化学工業株式会社製） ２．０ｇを含む精製水 ８．０ｇに分散させ、更にホモジナイザー（Ｐｏｌｙｔｒｏｎ ＰＴ−４５ ＫＩＮＥＭＡＴＩＣＡ社製）を用い、９，０００ｒｐｍで２０分間微細分散処理し、噴霧液とした。
(Example 1: Production of powder composition containing dead cells of lactic acid bacteria)
<Dispersing process>
Lactobacillus killed powder (EC-12, manufactured by Combi Corporation; bacteria number 5 trillions / g) of (Enterococcus faecalis (Enterococcus faecalis)) and 1.0 g, dextrin (Pinedex # 2, Matsutani Chemical Industry Co., Ltd. ) It was dispersed in 8.0 g of purified water containing 2.0 g, and further finely dispersed at 9,000 rpm for 20 minutes using a homogenizer (manufactured by Polytron PT-45 KINEMATICA) to obtain a spray solution.
＜流動層造粒工程＞
前記噴霧液の全量を、流動層造粒装置（フローコーター（ＦＬ−Ｌａｂｏ）、フロイント産業株式会社製）内に仕込んだオリゴ糖粉末（メイオリゴ、株式会社明治フードマテリア社製） ９７．０ｇに対して噴霧し、乳酸菌の死菌体含有粉末組成物を得た。
<Fluidized bed granulation process>
The total amount of the spray liquid was 97.0 g of oligosaccharide powder (Mayoligo, manufactured by Meiji Food Materia Co., Ltd.) charged in a fluidized bed granulator (Flow coater (FL-Labo), manufactured by Freund Sangyo Co., Ltd.). And sprayed to obtain a powder composition containing dead cells of lactic acid bacteria.
＜評価＞
前記乳酸菌の死菌体含有粉末組成物の水中における分散粒子径をレーザー回析／散乱式粒度分布測定装置（マイクロトラックＨＲＡ、日機装株式会社製）により測定した結果、５０％粒子径（体積基準の粒度分布の累積カーブを求めたとき、その累積カーブが５０％となる点の粒子径）は、０．６７μｍを示した。
したがって、本発明の製造方法により製造された乳酸菌の死菌体含有粉末組成物は、水性媒体への分散性に優れることが示された。
<Evaluation>
As a result of measuring the dispersed particle size of the powder composition containing dead cells of lactic acid bacteria in water with a laser diffraction / scattering particle size distribution measuring device (Microtrac HRA, manufactured by Nikkiso Co., Ltd.), a 50% particle size (volume basis) When the cumulative curve of the particle size distribution was determined, the particle diameter at the point where the cumulative curve was 50%) was 0.67 μm.
Therefore, it was shown that the dead bacterial cell-containing powder composition of lactic acid bacteria produced by the production method of the present invention is excellent in dispersibility in an aqueous medium.
（実施例２：乳酸菌の死菌体含有粉末組成物の製造）
＜分散工程＞
乳酸菌（エンテロコッカス・フェカリス（Ｅｎｔｅｒｏｃｏｃｃｕｓ ｆａｅｃａｌｉｓ））の死菌粉末（ＥＣ−１２、コンビ株式会社製；菌数 ５兆個／ｇ） ５００ｇを、デキストリン（ＮＳＤ＃３００、サンエイ糖化株式会社製） ３７５ｇを含む精製水 ２，０００ｇに分散させ、更にホモジナイザー（Ｔ−１８ ＩＫＡ社製）を用い、１４，０００ｒｐｍで１５分間微細分散処理し、噴霧液とした。
(Example 2: Production of powder composition containing dead cells of lactic acid bacteria)
<Dispersing process>
500 g of dead powder of lactic acid bacteria (Enterococcus faecalis) (EC-12, manufactured by Combi Corporation; number of bacteria 5 trillion / g) and 375 g of dextrin (NSD # 300, manufactured by Sanei Saccharification Co., Ltd.) It was dispersed in 2,000 g of purified water, and further finely dispersed at 14,000 rpm for 15 minutes using a homogenizer (manufactured by T-18 IKA) to obtain a spray solution.
＜流動層造粒工程＞
前記噴霧液の全量を、流動層造粒装置（フローコーター（ＦＬＯ−５）、フロイント産業株式会社製）内に仕込んだデキストリン粉末（ＮＳＤ＃３００、サンエイ糖化株式会社製） ４，１２５．０ｇに対して噴霧し、乳酸菌の死菌体含有粉末組成物を得た。
<Fluidized bed granulation process>
To the total amount of the spray solution 4,125.0 g of dextrin powder (NSD # 300, manufactured by Sanei Saccharification Co., Ltd.) charged in a fluidized bed granulator (Flow coater (FLO-5), manufactured by Freund Sangyo Co., Ltd.) On the other hand, a powder composition containing dead cells of lactic acid bacteria was obtained.
＜評価＞
前記乳酸菌の死菌体含有粉末組成物の水中における分散粒子径をレーザー回析／散乱式粒度分布測定装置（マイクロトラックＨＲＡ、日機装株式会社製）により測定した結果、５０％粒子径は０．７２μｍを示した。
したがって、本発明の製造方法により製造された乳酸菌の死菌体含有粉末組成物は、水性媒体への分散性に優れることが示された。
<Evaluation>
As a result of measuring the dispersed particle size of the powdered lactic acid bacteria-containing powder composition in water using a laser diffraction / scattering particle size distribution measuring device (Microtrac HRA, manufactured by Nikkiso Co., Ltd.), the 50% particle size was 0.72 μm. showed that.
Therefore, it was shown that the dead bacterial cell-containing powder composition of lactic acid bacteria produced by the production method of the present invention is excellent in dispersibility in an aqueous medium.
（実施例３：ビフィズス菌の死菌体含有粉末組成物の製造）
＜分散工程＞
死滅処理したビフィズス菌（ＢＲ−１０８、コンビ株式会社製）培養液（菌数 ３，０００億個／ｍＬ） ３３．４ｍＬに、デキストリン（パインデックス＃２、松谷化学工業株式会社製） ６．７ｇを分散溶解させ、更にホモジナイザー（Ｐｏｌｙｔｒｏｎ ＰＴ−４５ ＫＩＮＥＭＡＴＩＣＡ社製）を用い、９，０００ｒｐｍで２０分間微細分散処理し、噴霧液とした。
(Example 3: Production of powder composition containing dead cells of bifidobacteria)
<Dispersing process>
Bifidobacterium killed (BR-108, manufactured by Combi Co., Ltd.) culture solution (number of bacteria: 300 billion / mL) 33.4 mL, dextrin (paindex # 2, manufactured by Matsutani Chemical Co., Ltd.) 6.7 g Was dispersed and dissolved, and further finely dispersed at 9,000 rpm for 20 minutes using a homogenizer (Polytron PT-45 KINEMATICA) to obtain a spray solution.
＜流動層造粒工程＞
前記噴霧液の全量を、流動層造粒装置（フローコーター（ＦＬ−Ｌａｂｏ）、フロイント産業株式会社製）内に仕込んだオリゴ糖粉末（オリゴメイト５５ＮＰ、ヤクルト薬品工業株式会社製） ９０．０ｇに対して噴霧し、ビフィズス菌の死菌体含有粉末組成物を得た。
<Fluidized bed granulation process>
The total amount of the sprayed liquid is 90.0 g of oligosaccharide powder (oligomate 55NP, manufactured by Yakult Pharmaceutical Co., Ltd.) charged in a fluidized bed granulator (Flow coater (FL-Labo), manufactured by Freund Sangyo Co., Ltd.). On the other hand, a powder composition containing dead cells of bifidobacteria was obtained.
＜評価＞
前記ビフィズス菌の死菌体含有粉末組成物の水中における分散粒子径をレーザー回析／散乱式粒度分布測定装置（マイクロトラックＨＲＡ、日機装株式会社製）により測定した結果、５０％粒子径は、０．６８μｍを示した。
したがって、本発明の製造方法により製造されたビフィズス菌の死菌体含有粉末組成物は、水性媒体への分散性に優れることが示された。
<Evaluation>
As a result of measuring the dispersed particle size of the above-mentioned powder composition containing dead cells of bifidobacteria in water with a laser diffraction / scattering particle size distribution analyzer (Microtrac HRA, manufactured by Nikkiso Co., Ltd.), the 50% particle size was 0. .68 μm.
Therefore, it was shown that the dead cell-containing powder composition of Bifidobacterium produced by the production method of the present invention is excellent in dispersibility in an aqueous medium.
前記実施例１から３の結果から、本発明の製造方法によれば、水性媒体への分散性に優れ、飲料等の風味を変化させない乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物を簡易に、短時間で製造できることが示された。 From the results of Examples 1 to 3, according to the production method of the present invention, a powder composition containing dead cells of lactic acid bacteria and / or bifidobacteria that is excellent in dispersibility in an aqueous medium and does not change the flavor of beverages and the like. It was shown that it can be manufactured easily and in a short time.
Claims (3)
粉剤を仕込んだ流動層造粒装置内で前記噴霧液を噴霧する工程とを含むことを特徴とする乳酸菌及び／又はビフィズス菌の死菌体含有粉末組成物の製造方法。 A step of finely dispersing dead cells of lactic acid bacteria and / or bifidobacteria in a spray solution containing a water-soluble polymer substance;
A method for producing a powder composition containing dead cells of lactic acid bacteria and / or bifidobacteria, comprising a step of spraying the spray liquid in a fluidized bed granulator charged with a powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015100273A JP6616100B2 (en) | 2015-05-15 | 2015-05-15 | Process for producing powdered composition containing dead cells of lactic acid bacteria and / or bifidobacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015100273A JP6616100B2 (en) | 2015-05-15 | 2015-05-15 | Process for producing powdered composition containing dead cells of lactic acid bacteria and / or bifidobacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016214107A true JP2016214107A (en) | 2016-12-22 |
| JP6616100B2 JP6616100B2 (en) | 2019-12-04 |
Family
ID=57577502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015100273A Active JP6616100B2 (en) | 2015-05-15 | 2015-05-15 | Process for producing powdered composition containing dead cells of lactic acid bacteria and / or bifidobacteria |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6616100B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898815A (en) * | 2017-12-07 | 2018-04-13 | 生物源生物技术（深圳）股份有限公司 | A kind of animal inactivation lactobacillus preparation and application thereof |
| JP2019122316A (en) * | 2018-01-17 | 2019-07-25 | アサヒ飲料株式会社 | Container-packed coffee beverage and method for improving quality of taste of container-packed coffee beverage |
| JP2019187353A (en) * | 2018-04-27 | 2019-10-31 | アサヒ飲料株式会社 | Beverage, packed beverage, aggregation inhibition method of bacterial cell or bacterial cell processed product |
| WO2023008527A1 (en) | 2021-07-28 | 2023-02-02 | キリンホールディングス株式会社 | Lactobacillus-containing beverage and method for producing same |
Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03206870A (en) * | 1990-01-06 | 1991-09-10 | Kagome Kk | Production of granulated food |
| JP2002017337A (en) * | 2000-05-02 | 2002-01-22 | Biofuerumin Seiyaku Kk | Dried microbial cell by spray-drying |
| JP2003033173A (en) * | 2000-05-02 | 2003-02-04 | Biofuerumin Seiyaku Kk | Dried microbial cell by spray-drying |
| JP2006042805A (en) * | 2004-07-07 | 2006-02-16 | Toyo Shinyaku:Kk | Granule-containing processed barley young leaf |
| JP2006225380A (en) * | 2005-01-19 | 2006-08-31 | Rohto Pharmaceut Co Ltd | Immune balance regulator |
| JP2006230404A (en) * | 2005-01-31 | 2006-09-07 | Kirin Well Foods Co Ltd | Food or drug comprising lactic acid bacterium containing mineral |
| JP2007126365A (en) * | 2005-11-01 | 2007-05-24 | Momoya Co Ltd | Antiallergic agent comprising culture of lactobacillus plantarum as active ingredient |
| JP2007320946A (en) * | 2006-06-05 | 2007-12-13 | Advance Co Ltd | Composition for ameliorating intestinal flora |
| JP2007330177A (en) * | 2006-06-16 | 2007-12-27 | Asahi Kasei Chemicals Corp | Activator of enteric bacterium |
| JP2008307028A (en) * | 2007-06-18 | 2008-12-25 | Uha Mikakuto Co Ltd | Beverage composition and method for producing the same |
| JP2010090073A (en) * | 2008-10-09 | 2010-04-22 | Biofuerumin Seiyaku Kk | Prophylactic or therapeutic agent for nonspecific hypersensitivity of mucosa |
| JP2010095465A (en) * | 2008-10-16 | 2010-04-30 | House Wellness Foods Kk | Immunostimulating composition containing lactic acid bacterium |
| JP2010126700A (en) * | 2008-12-01 | 2010-06-10 | Sumitomo Bakelite Co Ltd | Polymeric compound for bioassay, and substrate for bioassay using the same |
| US20110070335A1 (en) * | 2008-05-23 | 2011-03-24 | Bruegger Juan-Carlos | Granulated dairy products |
| JP2011201840A (en) * | 2010-03-26 | 2011-10-13 | Meiji Co Ltd | Probiotics-containing composition filled with small content |
| JP2014054191A (en) * | 2012-09-11 | 2014-03-27 | Ogawa & Co Ltd | Powder acidulant composition and manufacturing method thereof |
| JP2014143986A (en) * | 2013-01-30 | 2014-08-14 | Ito En Ltd | Lactic acid bacteria-containing food products and manufacturing method thereof |
| JP2014162736A (en) * | 2013-02-22 | 2014-09-08 | Freunt Ind Co Ltd | Excipient agglomerated material, production method thereof, and tablet |
-
2015
- 2015-05-15 JP JP2015100273A patent/JP6616100B2/en active Active
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03206870A (en) * | 1990-01-06 | 1991-09-10 | Kagome Kk | Production of granulated food |
| JP2002017337A (en) * | 2000-05-02 | 2002-01-22 | Biofuerumin Seiyaku Kk | Dried microbial cell by spray-drying |
| JP2003033173A (en) * | 2000-05-02 | 2003-02-04 | Biofuerumin Seiyaku Kk | Dried microbial cell by spray-drying |
| JP2006042805A (en) * | 2004-07-07 | 2006-02-16 | Toyo Shinyaku:Kk | Granule-containing processed barley young leaf |
| JP2006225380A (en) * | 2005-01-19 | 2006-08-31 | Rohto Pharmaceut Co Ltd | Immune balance regulator |
| JP2006230404A (en) * | 2005-01-31 | 2006-09-07 | Kirin Well Foods Co Ltd | Food or drug comprising lactic acid bacterium containing mineral |
| JP2007126365A (en) * | 2005-11-01 | 2007-05-24 | Momoya Co Ltd | Antiallergic agent comprising culture of lactobacillus plantarum as active ingredient |
| JP2007320946A (en) * | 2006-06-05 | 2007-12-13 | Advance Co Ltd | Composition for ameliorating intestinal flora |
| JP2007330177A (en) * | 2006-06-16 | 2007-12-27 | Asahi Kasei Chemicals Corp | Activator of enteric bacterium |
| JP2008307028A (en) * | 2007-06-18 | 2008-12-25 | Uha Mikakuto Co Ltd | Beverage composition and method for producing the same |
| US20110070335A1 (en) * | 2008-05-23 | 2011-03-24 | Bruegger Juan-Carlos | Granulated dairy products |
| JP2010090073A (en) * | 2008-10-09 | 2010-04-22 | Biofuerumin Seiyaku Kk | Prophylactic or therapeutic agent for nonspecific hypersensitivity of mucosa |
| JP2010095465A (en) * | 2008-10-16 | 2010-04-30 | House Wellness Foods Kk | Immunostimulating composition containing lactic acid bacterium |
| JP2010126700A (en) * | 2008-12-01 | 2010-06-10 | Sumitomo Bakelite Co Ltd | Polymeric compound for bioassay, and substrate for bioassay using the same |
| JP2011201840A (en) * | 2010-03-26 | 2011-10-13 | Meiji Co Ltd | Probiotics-containing composition filled with small content |
| JP2014054191A (en) * | 2012-09-11 | 2014-03-27 | Ogawa & Co Ltd | Powder acidulant composition and manufacturing method thereof |
| JP2014143986A (en) * | 2013-01-30 | 2014-08-14 | Ito En Ltd | Lactic acid bacteria-containing food products and manufacturing method thereof |
| JP2014162736A (en) * | 2013-02-22 | 2014-09-08 | Freunt Ind Co Ltd | Excipient agglomerated material, production method thereof, and tablet |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898815A (en) * | 2017-12-07 | 2018-04-13 | 生物源生物技术（深圳）股份有限公司 | A kind of animal inactivation lactobacillus preparation and application thereof |
| JP2019122316A (en) * | 2018-01-17 | 2019-07-25 | アサヒ飲料株式会社 | Container-packed coffee beverage and method for improving quality of taste of container-packed coffee beverage |
| WO2019142793A1 (en) * | 2018-01-17 | 2019-07-25 | アサヒグループホールディングス株式会社 | Packaged coffee beverage and method for improving quality of taste of packaged coffee beverage |
| JP7117853B2 (en) | 2018-01-17 | 2022-08-15 | アサヒ飲料株式会社 | Packaged Coffee Beverage and Method for Improving Taste Quality of Packaged Coffee Beverage |
| JP2019187353A (en) * | 2018-04-27 | 2019-10-31 | アサヒ飲料株式会社 | Beverage, packed beverage, aggregation inhibition method of bacterial cell or bacterial cell processed product |
| JP7194511B2 (en) | 2018-04-27 | 2022-12-22 | アサヒ飲料株式会社 | Beverage, packaged beverage, method for suppressing aggregation of bacterial cells or treated bacterial cells, and method for producing beverage |
| WO2023008527A1 (en) | 2021-07-28 | 2023-02-02 | キリンホールディングス株式会社 | Lactobacillus-containing beverage and method for producing same |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6616100B2 (en) | 2019-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arepally et al. | Effect of inlet air temperature and gum Arabic concentration on encapsulation of probiotics by spray drying | |
| Linares et al. | Lactic acid bacteria and bifidobacteria with potential to design natural biofunctional health-promoting dairy foods | |
| Dianawati et al. | Survival of microencapsulated probiotic bacteria after processing and during storage: a review | |
| Quinto et al. | Probiotic lactic acid bacteria: a review | |
| Li et al. | Preparation of Bifidobacterium breve encapsulated in low methoxyl pectin beads and its effects on yogurt quality | |
| WO2017001590A1 (en) | Composition suitable for protecting microorganisms | |
| Gawkowski et al. | Non-dairy probiotic beverages: the next step into human health | |
| CN103180432B (en) | Prepare the method for shelf-stable probiotic food | |
| JP6616100B2 (en) | Process for producing powdered composition containing dead cells of lactic acid bacteria and / or bifidobacteria | |
| Vivek et al. | A comprehensive review on microencapsulation of probiotics: Technology, carriers and current trends | |
| Bhagwat et al. | Spray drying studies of probiotic Enterococcus strains encapsulated with whey protein and maltodextrin | |
| Nale et al. | Microbial viability, physicochemical and sensory properties of kefir microcapsules prepared using maltodextrin/Arabic gum mixes | |
| He et al. | Bifidobacterium spp. as functional foods: a review of current status, challenges, and strategies | |
| KR101583018B1 (en) | Lactobacillus capable of inducing production of IL-12 and method of preparing thereof | |
| Hossain et al. | Impact of encapsulating probiotics with cocoa powder on the viability of probiotics during chocolate processing, storage, and in vitro gastrointestinal digestion | |
| Thantsha et al. | Probiotics–what they are, their benefits and challenges | |
| Hathi et al. | Methodological advances and challenges in probiotic bacteria production: Ongoing strategies and future perspectives | |
| CN110193029B (en) | Colon-targeted drug delivery method of probiotics | |
| US20170280760A1 (en) | Method for the production of a porous powder product containing a probiotic or other microorganisms | |
| Murúa‐Pagola et al. | Protective effect of a cross‐linked starch by extrusion on the survival of Bifidobacterium breve ATCC 15700 in yogurt | |
| Dunne et al. | Role of probiotics in the treatment of intestinal infections and inflammation | |
| JP2008189572A (en) | Interleukin 12 production inhibitor | |
| JP7263678B2 (en) | Method for producing lactic acid bacteria-containing beverage with suppressed aggregation or sedimentation | |
| WO2019026743A1 (en) | Thickening composition for dysphagia patients | |
| Hati et al. | Encapsulation of probiotics for enhancing the survival in gastrointestinal tract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180223 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181225 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190220 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190319 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190514 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191029 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191107 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6616100 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |